Related Experiment Video

Updated: Aug 30, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Coxsackie-and-adenovirus receptor mRNA expression in human heart failure

A Sasse1, M Wallich1, Z Ding1

  • 1Institut für Herz- und Kreislaufphysiologie, Heinrich-Heine-University Duesseldorf, Universitaetsstr. 1, 40225 Duesseldorf, Germany.

The Journal of Gene Medicine
|October 9, 2003
PubMed
Abstract

Insights

Cardiomyopathies significantly increase coxsackie-and-adenovirus (CAR) receptor mRNA levels, enhancing adenoviral vector gene transfer for potential heart failure therapies.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Gene Therapy

Background:

  • Adenoviral vectors are common gene-transfer tools in research and clinical settings.
  • Transfection efficiency relies heavily on coxsackie-and-adenovirus (CAR) receptor concentration on target cells.

Purpose of the Study:

  • To quantify CAR receptor concentration in various human cardiomyopathies.
  • To assess the impact of cardiomyopathy on CAR receptor expression.

Main Methods:

  • Myocardial biopsies from patients with dilated CM, ischemic CM, and valve disease were analyzed.
  • Quantitative PCR measured CAR mRNA levels relative to GAPDH in patient samples and donor hearts.
  • CAR mRNA levels were compared across different cardiomyopathy types and to non-cardiomyopathic controls.

Main Results:

  • CAR mRNA levels were substantially elevated in all analyzed cardiomyopathies compared to non-cardiomyopathic hearts.
  • Dilated CM showed a 34-fold increase, ischemic CM a 12-fold increase, MVCM a 27-fold increase, and AVCM a 47-fold increase.
  • CAR levels in human ischemic CM were comparable to those in rat hearts.

Conclusions:

  • Cardiomyopathies significantly upregulate CAR-mRNA expression, averaging a 30-fold increase.
  • Enhanced CAR receptor levels suggest improved myocardial gene transfer using adenoviral vectors in cardiomyopathies.
  • This presents a promising avenue for therapeutic interventions in heart failure patients.

More Related Videos

Preparation of rAAV9 to Overexpress or Knockdown Genes in Mouse Hearts11:11

Preparation of rAAV9 to Overexpress or Knockdown Genes in Mouse Hearts

Published on: December 17, 2016

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...